Latest Advances in Lung Cancer Research

New treatments like immunotherapy and targeted therapy are improving post-surgery outcomes for lung cancer, with research ongoing to optimize these methods.

Patients with early-stage EGFR-mutated non-small cell lung cancer benefited from treatment with osimertinib, results of the phase 3 ADAURA trial showed.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

Mirati’s new lung cancer drug Krazati, targeting KRAS mutations, secures FDA approval, offering hope for advanced NSCLC patients.

Mirati’s adagrasib and Keytruda show promise for KRAS G12C-mutated NSCLC with a 49% tumor shrinkage in trials.

AstraZeneca and Daiichi Sankyo’s Enhertu scored an accelerated FDA approval in patients with HER2-mutant NSCLC.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.

New NSCLC targeted therapy guidelines have been published. They are updates to the 2017 systemic therapy recommendations.

Amivantamab Approved for EGFR Exon 20–Positive NSCLC. FDA approval marks this as a first treatment for patients with EGFR exon 20 insertion.

Sotorasib Approved for KRAS G12C NSCLC. First FDA approved treatment for KRAS-positive non small cell lung cancer.

An interview with Dr. Gregory Masters discussing the latest guidelines treating non-small cell lung cancer (NSCLC) with gene mutations.

Tepotinib approved for MET+ NSCLC treatment. Specifically, approval for metastatic NSCLC with MET exon 14 skipping alterations.